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LETTERS TO THE EDITOR
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0Regarding “A meta-analysis of clinical studies of
statins for prevention of abdominal aortic
aneurysm expansion”
Takagi et al1 performed a meta-analysis of the effects of statins
on abdominal aortic aneurysm (AAA) expansion and briefly dis-
cussed possible influences of this medication on aneurysm biology.
They report that treatment with statins was associated with a
decreased AAA progression, which was based on the most recent
available evidence at the time of submission (January 2010). How-
ever, as this topic is timely andmuch research is focused hereon, we
would like to address some relevant recent advances in current
knowledge.
A recently published large growth rate follow-up study did not
confirm previous findings of statins retarding AAA growth.2 This
study outnumbered previous observational studies by including
652 patients with small AAAs, of who 349 received statin treat-
ment. After adjustment for risk factors, statins were not found to
interfere with AAA growth (odds ratio, 1.23; 95% confidence
interval, 0.86-1.76), which also held true for the individual statins
(simvastatin 1.22 [0.72-2.05]; atorvastatin 0.95 [0.54-1.66];
pravastatin 1.78 [0.84-3.75]). In addition, a follow-up study of
4345 individuals for the detection of occurring incident AAA failed
to show a protective effect of statins on AAA development.3
Instead they described that after correction, statin use was associ-
ated with an increased risk for AAA (3.77 [1.45-9.81]), which was
attributed to a higher risk for cardiovascular diseases by the au-
thors, but subject to debate in the subsequent correspondence.4
Initial described attenuating effects of statins on proteases and
inflammation at the tissue level have also become more controver-
sial. We recently published an article involving harvested AAAwalls
of 216 patients undergoing open repair.5 In this observational
cohort study, 135 patients received a statin. After correction for
differences in baseline characteristics and risk factors, we found no
independent significant associations of statins as a group with
proteases, cytokines, and histology of collected AAA walls. Fur-
thermore, no individual statin stood out in any of the analyses
including those of inflammatory markers and proteases, contra-
dicting previously published smaller studies. This indicates that the
attributed pleiotropic effects of statin treatment on the AAA re-
main to be elucidated.
In summary, initially described attenuation of both AAA
growth rate and AAA wall proteases is becoming more controver-
sial because of recently published larger studies. Prospective clini-
cal trials are needed for determining the exact effects of statins on
the AAA progression and ultimately rupture. In the meantime,
with no detrimental effects on the AAA described, the use of statins
should be advocated in this group of patients with many cardio-
vascular risk factors in accordance with clinical guidelines.
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egarding “A meta-analysis of clinical studies of
tatins for prevention of abdominal aortic aneurysm
xpansion”
Takagi et al1 recently reported a meta-analysis of observational
tudies that related small abdominal aortic aneurysm (AAA) expan-
ion to prescription of statins. The authors concluded, “statin
herapy is associated with less expansion rates in patients with small
AA.” We believe this conclusion is not a correct interpretation of
he current data for a number of reasons.
First, there are no currently reported large randomized trials
ssessing the effect of statin prescription on outcomes for patients
ith small AAAs. The only randomized trial of statin prescription
hich we are aware of that reported AAA-specific outcomes was
he UK Heart Protection study.2 This randomized trial examined
he effect of statins on cardiovascular outcomes in 20,536 patients
ainly identified as having symptomatic coronary heart or periph-
ral artery disease. Given the association of both coronary heart
isease and peripheral artery disease with AAAs, it would have been
xpected that a significant number of patients with asymptomatic
AAs would also have been included in this study, although as far
s we are aware, routine aortic imaging was not included in the trial
rotocol.2
Although the trial demonstrated that important cardiovascu-
ar events, such as coronary events, strokes, and requirement for
evascularization, were substantially reduced by statin prescription,
he study reported no reduction in the frequency of AAA repair and
AA-related deaths, which was 1.2% in patients randomized to
tatins and 1.1% in those allocated placebo.2
Second, the meta-analysis of Takagi et al does not include a
umber of more recently published studies that together represent
ore than four times the number of patients in the present
eta-analysis (Table). None of these studies reported a significant
ssociation of statin prescription with aneurysm expansion. In one
f these studies, based on patients entered into the UK Small AAA
rial, patients prescribed statins had an average AAA expansion rate
f 1.92 mm/y, which was lower than the 2.81 mm/y result for
atients not prescribed this medication.3 This difference was not
ignificant, however.
In a recent report of the Chichester AAA screening study,
hompson et al4 found that the estimated annual expansion was
.47 mm/y in patients prescribed statins compared with 1.54
m/y in those who were not. In our multicenter study of patients
n Australia and New Zealand, we found that statin prescription
as not associated (odds ratio, 1.23; 95% confidence interval,
.86-1.76) with above-median AAA growth.5Third, publication bias may have also confounded the analysis
f Takagi et al. Most of the studies we were able to identify that
